CTOs on the Move

Eye Health Northwest

www.eyehealthnorthwest.com

 
Eye Health Northwest is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Swedish Medical Center

Swedish Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Seattle, WA. To find more information about Swedish Medical Center, please visit www.swedish.org

BIO- Medical Devices

BIO- Medical Devices is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoreLink Administrative Solutions

CoreLink Administrative Solutions was launched on January 1, 2009, as a new concept in health care benefits technology. We provide the technology that allows multiple companies to share common core systems and services, resulting in significant cost savings, gains in efficiency and improved capabilities to provide enhanced services. CoreLink is a long-term IT investment funded by Blue Cross Blue Shield of Nebraska and Blue Cross Blue Shield of North Dakota. Working together, the technology experts have built an infrastructure capitalizing on the strengths and experience of both Plans. This investment provides the means to efficiently address the ongoing changes in the health care environment and challenges posed by regulatory requirements, which can add significant costs to Plan operations.

Flyana.Com Inc

Flyana.Com Inc is a Anahola, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.